Provided by Tiger Trade Technology Pte. Ltd.

Health Care Select Sector SPDR Fund

166.18
-0.0200-0.01%
Post-market: 166.190.0101+0.01%19:55 EDT
Volume:7.15M
Turnover:1.19B
Market Cap:42.64B
PE:-11.69
High:166.85
Open:166.55
Low:165.27
Close:166.20
52wk High:176.60
52wk Low:141.05
Shares:256.62M
Float Shares:256.62M
Volume Ratio:0.83
T/O Rate:2.79%
Dividend:2.45
Dividend Rate:1.47%
EPS(TTM):-14.2170
EPS(LYR):-14.2170
ROE:-9.22%
ROA:1.03%
PB:1.24
PE(LYR):-11.69

Loading ...

Ramsay Health Care Lifts CEO Maximum LTI Opportunity

MT Newswires Live
·
Sep 24

HealthCo Healthcare and Wellness REIT Says Perth Hospital Completes Transition to New Operator

MT Newswires Live
·
Sep 24

Ramsay Health Care refreshes board with retirement of long-serving director and appointment of Dr Tracey Batten

TIPRANKS
·
Sep 24

Ramsay boosts CEO long-term incentive while holding base pay steady

TIPRANKS
·
Sep 24

Healthcare Stocks Fall

Dow Jones
·
Sep 24

Medtronic PLC Stock Underperforms Wednesday When Compared to Competitors

Dow Jones
·
Sep 24

Eli Lilly & Co. Stock Underperforms Wednesday When Compared to Competitors

Dow Jones
·
Sep 24

Analyst Reiterates Buy on Viking as VK2735 Data Support Differentiated Obesity Franchise; $70 Price Target Maintained

TIPRANKS
·
Sep 24

Analysts Are Bullish on These Healthcare Stocks: Immunovant (IMVT), Oruka Therapeutics (ORKA)

TIPRANKS
·
Sep 24

Exchange-Traded Funds, US Equities Decline After Midday

MT Newswires Live
·
Sep 24

Stringer Reiterates Buy on Ionis as Late-Stage Pipeline Delivers; Price Target Maintained at $86

TIPRANKS
·
Sep 24

Worldwide Healthcare Trust Boosts Treasury Stock with New Share Buyback

TIPRANKS
·
Sep 24

Health Care Roundup: Market Talk

Dow Jones
·
Sep 24

Johnson & Johnson Says New Analysis of Ongoing Phase 3 Trial Data Supports Potential of Multiple Myeloma Combination Therapy

MT Newswires Live
·
Sep 23

Bamboos Health Care Profit Slumps but Dividend Raised Amid Revenue Decline

TIPRANKS
·
Sep 23

Bamboos Health Care Announces Final Dividend for FY2026

TIPRANKS
·
Sep 23

J&J Says New Model-Based Analysis Further Supports the Potential of Tecvayli Plus Darzalex Faspro

Reuters
·
Sep 23

Johnson & Johnson: Phase 3 MajesTEC-3 study shows ‘sustained’ disease control

TIPRANKS
·
Sep 23

J&J Says MajesTEC-3 Analysis Projects Near-General-Population Mortality Risk for Tecvayli-Darzalex Combo in Early Relapsed Myeloma

Reuters
·
Sep 23

J&J - Tecvayli Plus Darzalex Faspro Reduces Multiple Myeloma Progression Risk by 90% Versus Standard of Care

THOMSON REUTERS
·
Sep 23